HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis

Pediatric Allergy and Immunology

Volumn 20, Issue 3, 2009, Pages 287-294

  Tripathy, Ita ^a   Levy, Arden ^b   Ratner, Paul ^c   Clements, Diane ^d   Wu, Wei ^d   Philpot, Edward ^d  

^a Phelps County Regional Medical Center   (United States)

^b Spartanburg Medical Research ^*  (United States)

^c Sylvana Research   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Cortisol production; Fluticasone furoate; Hypothalamic pituitary adrenal axis; Intranasal corticosteroids; Pediatric patients; Perennial allergic rhinitis

Indexed keywords

FLUTICASONE FUROATE; HYDROCORTISONE; PLACEBO;

ANAMNESIS; ARTICLE; CHILD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; EAR INFECTION; FEMALE; FEVER; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LUNG EMPHYSEMA; MAJOR CLINICAL STUDY; MALE; NOSE DISEASE; PERENNIAL RHINITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; URTICARIA;

ADMINISTRATION, INTRANASAL; ANDROSTADIENES; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY-ADRENAL SYSTEM; RHINITIS, ALLERGIC, PERENNIAL;

EID: 65349107125     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2008.00775.x     Document Type: Article

References (23)

1. Bellanti JA, Wallerstedt DB. Allergic rhinitis update: epidemiology and natural history. Allergy Asthma Proc 2000 : 21 : 367 70.
2. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 2001 : 22 : 185 9.
3. Berger WE. Allergic rhinitis in children: diagnosis and management strategies. Paediatr Drugs 2004 : 6 : 233 50.
4. Fireman P. Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol 2000 : 105 : S616 21.
5. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002 : 89 : 479 84.
6. Fokkens WJ, Cserhati E, dos Santos JM, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol 2002 : 89 : 279 84.
7. Richards DH, Milton CM. Fluticasone propionate aqueous nasal spray: a well-tolerated and effective treatment for children with perennial rhinitis. Pediatr Allergy Immunol 1996 : 7 : 35 43.
8. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001 : 108 : S147 334.
9. Stanbury RM, Graham EM. Systemic corticosteroid therapy - side effects and their management. Br J Ophthalmol 1998 : 82 : 704 8.
10. Bousquet J, van Cauwenberge P, Bachert C, et al. Requirements for medications commonly used in the treatment of allergic rhinitis. European Academy of Allergy and Clinical Immunology (EAACI), Allergic Rhinitis and its Impact on Asthma (ARIA). Allergy 2003 : 58 : 192 7.
11. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998 : 81 : 478 518.
12. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc 2004 : 1 : 171 5.
13. Lipworth BJ, Jackson CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Saf 2000 : 23 : 11 33.
14. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther 1997 : 19 : 1330 9.
15. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics 2003 : 112 : 96 100.
16. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000 : 105 : E22.
17. Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol 1998 : 101 : 157 62.
18. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv 2007 : 4 : 689 701.
19. Martin BG, Ratner PH, Hampel FC, et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007 : 28 : 216 25.
20. Allen A, Down G, Newlands A, Rousell V, Salmon E. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects. Ann Allergy Asthma Immunol 2007 : 98 : A89.
21. US Department of Health and Human Services, National Heart LaBI, National Institutes of Health, Public Health Service. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. NIH Publication No. 97-4051. 1997.
22. Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur J Clin Pharmacol 2004 : 60 : 265 8.
23. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000 : 106 : S179 90.